Gross Jane A 4

What Happened
Jane A. Gross, a member of the Board of Directors of aTYR PHARMA INC (ATYR), was granted a 50,000-share derivative award (reported as acquisition code "A") on May 11, 2026. The filing reports $0.00 per share (no cash paid) for a derivative award under the issuer’s non-employee director compensation policy.

Key Details

• Transaction date: 2026-05-11; Form 4 filed: 2026-05-13 (timely reporting).
• Transaction type: Award/Grant of a derivative (option-type) award — 50,000 shares reported at $0.00.
• Reported value: $0 (award/derivative reported rather than a market purchase).
• Vesting: Award vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer’s 2027 Annual Meeting of Stockholders, subject to Gross’s continued board service (per footnote).
• Shares owned after transaction: not specified in the provided filing details.

Context
This is a director compensation grant (routine for non-employee directors), not an open-market purchase or sale. As a derivative award, it gives the right to acquire shares subject to vesting and any exercise terms; it is not an immediate purchase or sale of stock and does not necessarily signal the insider buying or selling shares.